ORTX - Orchard Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.20
-0.20 (-1.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.40
Open13.56
Bid10.16 x 1100
Ask17.86 x 800
Day's Range13.11 - 13.66
52 Week Range9.78 - 21.64
Volume134,549
Avg. Volume299,430
Market Cap1.274B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.57
  • Gene therapy company eyes adding 100 jobs at new East Bay plant
    American City Business Journals

    Gene therapy company eyes adding 100 jobs at new East Bay plant

    A London-based company setting up a series of one-dose-and-done gene therapies will begin construction in the first half of this year of a nearly 200-employee manufacturing facility in Fremont. Orchard Therapeutics plc (NASDAQ: ORTX) hopes to open the 152,995-square-foot facility by the end of 2021 to make gene therapies and viral vectors, the shells of a deactivated virus that carry genes that correct a genetic mutation. Orchard already has a manufacturing support team in Menlo Park of between 80 and 90 people who will move to the new facility.

  • GlobeNewswire

    Orchard Therapeutics Highlights 2020 Strategic Priorities

    BOSTON and LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a global gene therapy leader, today outlined the company’s strategic priorities and recent progress in conjunction with its attendance at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Mark Rothera, Orchard’s president and chief executive officer, will present a business overview on Tuesday, January 14, 2020 at 11:30 a.m. PT that will be webcast live at ir.orchard-tx.com.

  • GlobeNewswire

    Orchard Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BOSTON and LONDON, Jan. 06, 2020 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • Is Orchard Therapeutics plc (ORTX) A Good Stock To Buy ?
    Insider Monkey

    Is Orchard Therapeutics plc (ORTX) A Good Stock To Buy ?

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • GlobeNewswire

    Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, will be presenting new registrational data from multiple programs at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2019 in Orlando, FL. On Sunday, December 8, 2019, investigators will describe ongoing clinical progress for two lead development programs in the company’s primary immune deficiencies portfolio: OTL-103, an investigational gene therapy in development for the treatment of Wiskott-Aldrich syndrome (WAS) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy; and OTL-101, an investigational gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID).

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Benzinga

    The Gene Therapy Names Moving On The Audentes Buyout Deal

    Gene therapy company Audentes Therapeutics Inc (NASDAQ: BOLD ) announced a deal late Monday to be acquired by Japanese pharma company ASTELLAS PHARMA/ADR (OTC: ALPMY ) for $60 per share, representing a ...

  • GlobeNewswire

    Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorization Application (MAA) for OTL-200, an ex vivo, autologous, hematopoietic stem cell-based gene therapy that has been developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, for the treatment of metachromatic leukodystrophy (MLD). “We are pleased that OTL-200 for the treatment of MLD is now under review with the EMA, bringing us another step closer to potentially making an approved gene therapy treatment a reality for children and families affected by this devastating and rapidly progressing disease,” said Mark Rothera, president and chief executive officer of Orchard Therapeutics.

  • GlobeNewswire

    European Medicines Agency Grants Orchard Therapeutics Accelerated Assessment of OTL-200 for Patients with Metachromatic Leukodystrophy

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for OTL-200, a gene therapy in development for the treatment of metachromatic leukodystrophy (MLD) in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. “We are pleased that OTL-200 has been granted accelerated assessment and believe this underscores the quality of our clinical data and the urgent need to bring this novel, potentially curative treatment option to patients living with MLD,” said Anne Dupraz-Poiseau, Ph.D., chief regulatory officer of Orchard Therapeutics.

  • FDA approves Acceleron's blood disorder drug ahead of schedule
    American City Business Journals

    FDA approves Acceleron's blood disorder drug ahead of schedule

    Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.

  • GlobeNewswire

    Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises

    ASH Abstracts Published Today Confirm Achievement of All Key Endpoints in Wiskott-Aldrich Syndrome Registrational Trial and Demonstrate Consistency of Data Between the Fresh and.

  • GlobeNewswire

    Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the upcoming presentation of registrational data from multiple programs at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL. Investigators will describe ongoing clinical progress for two lead development programs in the company’s primary immune deficiencies portfolio: OTL-103, an investigational gene therapy in development for the treatment of Wiskott-Aldrich syndrome (WAS) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy; and OTL-101, an investigational gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID).

  • Did Changing Sentiment Drive Orchard Therapeutics's (NASDAQ:ORTX) Share Price Down By 16%?
    Simply Wall St.

    Did Changing Sentiment Drive Orchard Therapeutics's (NASDAQ:ORTX) Share Price Down By 16%?

    Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...

  • GlobeNewswire

    Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results

    BOSTON and LONDON, Oct. 30, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • Hedge Funds Have Never Been This Bullish On Orchard Therapeutics plc (ORTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Orchard Therapeutics plc (ORTX)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • GlobeNewswire

    Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced initial results from a clinical trial with a cryopreserved formulation of OTL-200, a gene therapy in development for the treatment of metachromatic leukodystrophy (MLD) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. The initial data show that cellular engraftment with OTL-200 using a cryopreserved formulation is similar to that observed using a fresh formulation with the longest patient having 12 months of follow-up since treatment.

  • GlobeNewswire

    Orchard Therapeutics Announces Appointment of CEO Mark Rothera to The Alliance for Regenerative Medicine’s 2020 Board of Directors

    BOSTON and LONDON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company’s president and chief executive officer, Mark Rothera, has been appointed to The Alliance for Regenerative Medicine’s (ARM) 2020 Board of Directors. ARM is the leading international multi-stakeholder advocacy organization for the cell and gene therapy sector, promoting legislative, regulatory, and reimbursement initiatives to facilitate access to life-giving advances in regenerative medicine worldwide. “This is an incredibly exciting time in medicine, as we work to bring transformative – potentially even curative – new treatments to patients around the world.

  • GlobeNewswire

    Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the presentation of new clinical data at the upcoming European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Barcelona, Spain, October 22-25, 2019. The poster presentation will highlight initial results from the ongoing clinical trial with a cryopreserved formulation of OTL-200 for metachromatic leukodystrophy (MLD) that is being conducted at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

  • GlobeNewswire

    Orchard Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BOSTON and LONDON, Sept. 25, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire

    Orchard Therapeutics Announces Departure of Chief Commercial Officer

    BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that chief commercial officer Jason Meyenburg is leaving the company effective today to take on a chief executive role in the industry. In the interim Mark Rothera, the company’s president and chief executive officer, will assume global commercial leadership responsibilities.

  • GlobeNewswire

    Orchard Therapeutics Announces Encouraging Update from Proof-of-Concept Study of OTL-203 for the Treatment of Mucopolysaccharidosis Type I (MPS-I)

    Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment Evidence of Engraftment and Peripheral Blood Alpha-L-iduronidase.

  • GlobeNewswire

    Orchard Therapeutics Presents an Integrated Data Analysis Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of Metachromatic Leukodystrophy

    Further Demonstration that OTL-200 Provides Meaningful Clinical Benefit on Cognitive and Motor Function No Standard Treatment Options Available, Regulatory Submission in Europe.

  • GlobeNewswire

    Orchard Therapeutics to Webcast Presentation at the Morgan Stanley 17th Annual Global Healthcare Conference

    BOSTON and LONDON, Sept. 03, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire

    Orchard Therapeutics Further Strengthens Board of Directors with Appointment of John Curnutte, M.D., Ph.D.

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of John Curnutte, M.D., Ph.D., to its board of directors. Dr. Curnutte brings more than 26 years of research and development expertise in both the biotechnology and pharmaceutical sectors. Mark Rothera, president and chief executive officer of Orchard, said, “We are at an exciting juncture in our growth as a company as we have an extensive product pipeline with three regulatory filings expected by the end of 2021, making this an opportune time for John to join our Board of Directors.

  • GlobeNewswire

    Orchard Therapeutics Announces Presentation of Data from Neurometabolic Portfolio at Upcoming Society for the Study of Inborn Errors of Metabolism (SSIEM) 2019 Annual Symposium

    BOSTON and LONDON, Aug. 27, 2019 -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.